Missense Mutations of MADH4

Purpose and Experimental Design: The mutational spectrum of MADH4 (DPC4/SMAD4) opens valuable insights into the functions of this protein that confer its tumor-suppressive nature in human tumors. We present the MADH4 genetic status determined on a new set of pancreatic, biliary, and duodenal cancers with comparison to the mutational data reported for various tumor types. Results: Homozygous deletion, followed by inactivating nonsense or frameshift mutations, is the predominant form of MADH4 inactivation in pancreatic cancers. Among the naturally occurring MADH4 missense mutations, the MH2 domain is the most frequent target (77%) of missense mutations in human tumors. A mutational hot spot resides within the MH2 domain corresponding to codons 330 to 370, termed the mutation cluster region (MCR). A relationship was found between the locations of the missense mutations (the MH1 domain, the MH2-MCR, and the MH2 outside of the MCR) and the tumor types, suggesting environmental or selective influences in the development of MADH4 mutations. Immunohistochemical studies for Madh4 protein in nine archival cancers (six pancreatic cancers, two duodenal cancers, and one biliary cancer) with known missense mutations indicated that all mutations within the MH1 or MH2 domain COOH-terminal to the MCR (seven of nine cases) had negative or weak labeling, whereas two cancers with mutations within the MCR had strong positive nuclear labeling for Madh4 protein. Conclusions: These findings have important implications for in vitro functional studies, suggesting that the majority of missense mutations inactivate Madh4 by protein degradation in contrast to those that occur within the MCR.

[1]  K. Vähäkangas.  TP53 mutations in workers exposed to occupational carcinogens , 2003, Human mutation.

[2]  G. Klöppel,et al.  Tumor-Suppressing Pathways in Cystic Pancreatic Tumors , 2003, Pancreas.

[3]  E. Fontham,et al.  Differences in KRAS mutation spectrum in lung cancer cases between African Americans and Caucasians after occupational or environmental exposure to known carcinogens. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[4]  R. Hruban,et al.  K-ras, p53, and DPC4 (MAD4) alterations in fine-needle aspirates of the pancreas: a molecular panel correlates with and supplements cytologic diagnosis. , 2002, American journal of clinical pathology.

[5]  R. Penzel,et al.  Genetics of adenocarcinomas of the small intestine: frequent deletions at chromosome 18q and mutations of the SMAD4 gene , 2002, Oncogene.

[6]  T. Muir,et al.  Crystal structure of a phosphorylated Smad2. Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-beta signaling. , 2001, Molecular cell.

[7]  C. Hill,et al.  Loss of Smad4 Function in Pancreatic Tumors , 2001, The Journal of Biological Chemistry.

[8]  Wei Zhang,et al.  Aberrant expression of Smad4 results in resistance against the growth‐inhibitory effect of transforming growth factor‐β in the SiHa human cervical carcinoma cell line , 2001, International journal of cancer.

[9]  L. Aaltonen,et al.  Comprehensive analysis of SMAD4 mutations and protein expression in juvenile polyposis: evidence for a distinct genetic pathway and polyp morphology in SMAD4 mutation carriers. , 2001, The American journal of pathology.

[10]  W. F. Bodmer,et al.  SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microsatellite instability pathway , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  R. Fairman,et al.  Formation of a Stable Heterodimer between Smad2 and Smad4* , 2001, The Journal of Biological Chemistry.

[12]  T. Urano,et al.  Somatic alterations of the DPC4 and Madr2 genes in colorectal cancers and relationship to metastasis. , 2001, International journal of oncology.

[13]  Shigeru Chiba,et al.  Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis , 2001, Oncogene.

[14]  A. Scarpa,et al.  Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis , 2001, British Journal of Cancer.

[15]  C. Heldin,et al.  Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4 , 2000, Oncogene.

[16]  S. Kern,et al.  Functional mapping of the MH1 DNA-binding domain of DPC4/SMAD4. , 2000, Nucleic acids research.

[17]  H. Choi,et al.  Germline mutations of the dpc4 gene in Korean juvenile polyposis patients , 2000, International journal of cancer.

[18]  W. Bodmer,et al.  Analysis of genetic and phenotypic heterogeneity in juvenile polyposis , 2000, Gut.

[19]  L. Attisano,et al.  Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  R. Hruban,et al.  Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. , 2000, Cancer research.

[21]  K. Miyazono,et al.  Region between α‐helices 3 and 4 of the Mad homology 2 domain of Smad4: functional roles in oligomer formation and transcriptional activation , 1999, Genes to cells : devoted to molecular & cellular mechanisms.

[22]  M. Ozturk,et al.  Smad2 and Smad4 gene mutations in hepatocellular carcinoma , 1999, Oncogene.

[23]  M. Stolte,et al.  Frequent 4‐bp deletion in exon 9 of the SMAD4/MADH4 gene in familial juvenile polyposis patients , 1999, Genes, chromosomes & cancer.

[24]  M. Emi,et al.  Inactivation of both alleles of the DPC4/SMAD4 gene in advanced colorectal cancers: identification of seven novel somatic mutations in tumors from Japanese patients. , 1999, Mutation research.

[25]  Takeo Iwama,et al.  Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis , 1999, Oncogene.

[26]  M. Rothmund,et al.  Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors , 1999, Oncogene.

[27]  A. Okamoto,et al.  Allelic imbalance in chromosome band 18q21 and SMAD4 mutations in ovarian cancers , 1999, Genes, chromosomes & cancer.

[28]  A. Andrén-sandberg,et al.  Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer , 1999, Genes, chromosomes & cancer.

[29]  W. Bodmer,et al.  Mutations in DPC4 (SMAD4) cause juvenile polyposis syndrome, but only account for a minority of cases. , 1998, Human molecular genetics.

[30]  S. Kern,et al.  Dpc4 transcriptional activation and dysfunction in cancer cells. , 1998, Cancer research.

[31]  Yigong Shi,et al.  Crystal Structure of a Smad MH1 Domain Bound to DNA Insights on DNA Binding in TGF-β Signaling , 1998, Cell.

[32]  Denis Vivien,et al.  Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the promoter of human plasminogen activator inhibitor‐type 1 gene , 1998, The EMBO journal.

[33]  W. Schmiegel,et al.  Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. , 1998, Cancer research.

[34]  K. Kinzler,et al.  Human Smad3 and Smad4 are sequence-specific transcription activators. , 1998, Molecular cell.

[35]  Xiao-Fan Wang,et al.  Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein , 1997, Molecular and cellular biology.

[36]  D. Slamon,et al.  Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas , 1997, Oncogene.

[37]  Kirby D. Johnson,et al.  Drosophila Mad binds to DNA and directly mediates activation of vestigial by Decapentaplegic , 1997, Nature.

[38]  Yigong Shi,et al.  A structural basis for mutational inactivation of the tumour suppressor Smad4 , 1997, Nature.

[39]  J. Massagué,et al.  Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4 , 1997, Nature.

[40]  A. Roberts,et al.  Characterization of Functional Domains within Smad4/DPC4* , 1997, The Journal of Biological Chemistry.

[41]  C. Moskaluk,et al.  Genomic Sequencing of DPC4 in the Analysis of Familial Pancreatic Carcinoma , 1997, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[42]  Y. Takagi,et al.  Somatic alterations of the DPC4 gene in human colorectal cancers in vivo. , 1996, Gastroenterology.

[43]  Scott E. Kern,et al.  Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers , 1996, Nature Genetics.

[44]  Y. Yatabe,et al.  Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. , 1996, Cancer research.

[45]  J. Massagué,et al.  A human Mad protein acting as a BMP-regulated transcriptional activator , 1996, Nature.

[46]  Kathleen R. Cho,et al.  DPC4 gene in various tumor types. , 1996, Cancer research.

[47]  C. Moskaluk,et al.  Homozygous deletion map at 18q21.1 in pancreatic cancer. , 1996, Cancer research.

[48]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[49]  R. Hruban,et al.  Allelotype of pancreatic adenocarcinoma using xenograft enrichment. , 1995, Cancer research.

[50]  R. Hruban,et al.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.

[51]  B. Vogelstein,et al.  Transforming growth factor-beta-induced growth inhibition in a Smad4 mutant colon adenoma cell line. , 2001, Cancer research.

[52]  L. Grochow,et al.  Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  A. Sparks,et al.  Immunohistochemical labeling for Dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation , 2000 .

[54]  B. Qin,et al.  Crystal structure of a transcriptionally active Smad4 fragment. , 1999, Structure.

[55]  T. Mitsudomi,et al.  Somatic in vivo alterations of the DPC4 gene at 18q21 in human lung cancers. , 1996, Cancer research.